Conclusions
1 evidence topic · 15 sources
Summary
Cretostimogene grenadenorepvec is investigational; its safety and efficacy “have not been established by the FDA or any other health authority”. The rolling BLA, initiated in November 2025, is to include both CIS and high-grade papillary-only disease after FDA feedback, with completion anticipated in March 2027. No price has been announced.
The efficacy evidence comes from single-arm studies. In the phase 3 BOND-003 Cohort C, 83 of 110 participants (75.5%) had a complete response at any time as of the June 23, 2025 cutoff; landmark complete response was 46.4% at 12 months and 41.8% at 24 months, and median duration of response was 27.9 months. In Cohort P (papillary-only disease), estimated 9-month HG-EFS was 80.4% in 51 efficacy evaluable participants as of the September 1, 2025 cutoff. In the phase 2 CORE-001 trial with pembrolizumab, complete response at 12 months was 57.1% (20 of 35). Treatment-related adverse events occurred in 71 of 112 participants (63.4%) in Cohort C and 40 (71.4%) in Cohort P, none of grade 3 or higher.
The EAU guideline describes radical cystectomy as “the standard and preferred option”. Nadofaragene firadenovec, pembrolizumab, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system were each evaluated in single-arm trials, with labeled complete response rates of 51%, 41%, 62%, and 82%, respectively.
No randomized comparison of cretostimogene with any of these options and no health-related quality of life results were identified. Only the abstract of the peer-reviewed Cohort C report could be quoted, and the prespecified statistical threshold was not found. For the same cutoff, company documents report 12- and 24-month duration of response of 64.2% and 60.1% in a 2026 presentation and 64.1% and 58.3% in the Form 10-K, and describe Cohort P as “an exploratory study” in the Form 10-K and as “currently not intended for regulatory approval” in a 2026 investor presentation.